UC San Diego Shiley Eye Institute UC San Diego Shiley Eye Institute The Viterbi Family Department of Ophthalmology UC San Diego Shiley Eye Institute
by name
Afshari, Natalie A. Baxter, Sally L. Borooah, Shyamanga Brown, Stuart I. Camp, Andrew Do, Jiun Ferreyra, Henry A. Freeman, William R. Girkin, Christopher Goldbaum, Michael H. Granet, David B. Haw, Weldon W. Heichel, Chris W. Hennein, Lauren Huang, Alex A. Huang, Lingling Kikkawa, Don O. Kline, Lanning Korn, Bobby S. Lee, Jeffrey E. Liu, Catherine Y. Moghimi, Sasan Movaghar, Mansoor Nguyen, Thao P. Nudleman, Eric Puig-Llano, Manuel Robbins, Shira L. Rudell, Jolene Savino, Peter J. Scott, Nathan L. Spencer, Doran B. Toomey, Christopher B. Vasile, Cristiana Weinreb, Robert N. Welsbie, Derek S.
by specialty
Comprehensive Ophthalmology Cornea & Cataracts Dry Eye Clinic Glaucoma Neuro-Ophthalmology Ocular Oncology Ophthalmic Genetics Ophthalmic Pathology Ophthalmic Plastic & Reconstructive Surgery Ophthalmology Informatics and Data Science Optometry & Low Vision Pediatric Ophthalmology & Eye Alignment Disorders Refractive Surgery / LASIK Retina & Vitreous Thyroid Eye Clinic Uveitis
by condition
AMD (Age-related Macular Degeneration) Cataracts Corneal Conditions Cosmetic Surgery Diabetic Retinopathy Eye Cancer Eye Movement Disorders Glaucoma Hereditary (Genetic) Disorders Low Vision Neuro-Ophthalmic Conditions Ophthalmic Plastic and Reconstructive Surgery Pediatric Conditions Refractive Errors Retinal Diseases Strabismus (Strabimus) Thyroid Eye Disease Uveitis
Events Banner

UC San Diego Joins NIH ‘Bridge to Artificial Intelligence’ Program

The NIH Common Fund’s initiative will expand the use of artificial intelligence to solve pressing challenges in human health

Researchers at University of California San Diego School of Medicine have been selected to lead components of the National Institutes of Health (NIH) Common Fund’s Bridge to Artificial Intelligence (Bridge2AI) program. Over the next four years, Bridge2AI will award $130 million to accelerate the widespread use of AI in biomedical research and health care.

Physicians and scientists have long recognized the potential of AI to help understand and treat disease, but its use in clinical and research settings remains limited. This is, in part, because AI tools cannot always be easily or appropriately applied to new datasets that were not organized for this type of analysis. Furthermore, most AI algorithms function as “black boxes” — when they reach a conclusion about something, no one knows exactly how or why that decision was made.

To address these issues, Bridge2AI will fund four Data Generation Projects to create comprehensive AI-ready datasets that will lay the groundwork for new, interpretable and trustworthy AI technologies. The four multi-site projects will be unified by the Bridge Center, an executive hub that oversees the integration, dissemination and evaluation of all Bridge2AI activities.

Trey Ideker, PhD, professor at UC San Diego School of Medicine, will serve as principal investigator for one of the Data Generation Projects. Lucila Ohno-Machado, MD, PhD, professor and associate dean for informatics and technology at UC San Diego School of Medicine, will serve as a principal investigator for the Bridge Center.

“This is the first time NIH has invested in biomedical AI at this scale, and we are thrilled to be a part of it,” said Ideker. “UC San Diego has proven itself to be a pioneer in clinical and research AI technology, but this funding will help cement our place in the AI revolution.”

 

Cell Maps for AI

Ideker and collaborators are expected to receive nearly $20 million in the next four years to launch Cell Maps for AI, a research project designed to usher in a new era of precision medicine. The team envisions a future in which an AI algorithm could analyze a patient’s genome and decipher which disease they have, what stage they are in and which treatments are most likely to help. Importantly, they say the algorithm must be interpretable, such that a physician could point to the molecular and cellular pathways that inform its decisions.

“It’s not enough for an algorithm to just take a complex set of mutations and decide what drug to give a patient if we don’t know why it’s making that choice,” said Ideker. “We may now have enough human genomes sequenced to power precision medicine, but what we don’t have yet is a clear map of cellular biology to interpret the data with.”

To address this, the project aims to map the structure and function of a human cell in its entirety, starting with the most basic cell type: the stem cell. The researchers will obtain induced pluripotent stem cells from a variety of genetic backgrounds and combine microscopy, biochemistry and computational tools to study their biology at multiple scales. The final product will be a comprehensive model of the cell, from genes and proteins to entire organelles and how they all work together. Once the stem cell has been modeled, they plan to use the same approach to model other cells, such as those that are dividing, differentiating or in various disease states.

Their goal is to eventually have a library of cell maps across many demographic and disease contexts, which can be used to train AI algorithms to make informed and interpretable decisions about human health.

“With Bridge2AI, we are not only generating unprecedented datasets, but also developing a system to do this work in an organized and ethical way, which will set the field up for future success,” Ideker said.

Additional principal investigators on the project include Prashant Mali, PhD, at the UC San Diego Jacobs School of Engineering and researchers at UC San Francisco, Stanford University, University of Alabama, University of Alabama at Birmingham, University of Montreal, Simon Fraser University, University of South Florida, University of Texas at Austin, University of Virginia and Yale University.


Bridge Center

Coordinating all program efforts is the Bridge Center, consisting of six cores focused on Administration, Ethics, Teaming, Standards, Tool Optimization and Skills and Workforce Development. UC San Diego is expected to receive nearly $10 million over four years to lead both the Administrative and Ethics Cores.

“Leading the Bridge Center is exciting in many ways,” said Ohno-Machado. “In addition to supporting this groundbreaking and interdisciplinary research, we will also spearhead new models of scientific collaboration, ensure the training of a highly diverse group of researchers and ultimately build AI tools that are truly applicable to everyone.”

Ohno-Machado will lead the Bridge Center Administrative Core and co-lead the Ethics Core with Camille Nebeker, EdD, at the Herbert Wertheim School of Public Health and Human Longevity Science at UC San Diego. Other UC San Diego investigators include Cinnamon Bloss, PhD, also at the Herbert Wertheim School of Public Health, Tsung-Ting Kuo, PhD, UC San Diego School of Medicine, and Jingbo Shang, PhD, Babak Salimi, PhD, and Berk Ustun, PhD, all at Jacobs School of Engineering and the Halıcıoğlu Data Science Institute. Additional Bridge Center collaborators include faculty at the Broad Institute, Vanderbilt University and University of Texas Health.

Nebeker, along with UC San Diego School of Medicine faculty Sally Baxter, MD, and Linda Zangwill, PhD, are also leading modules within another Data Generation Project called AI Ready and Equitable Atlas for Diabetes Insights (AI-READI), led by principal investigators at University of Washington. The project will generate an ethically sourced data repository to develop machine learning models with the goal of learning how Type 2 diabetes is influenced by patients’ genes, lifestyle and environments.

“Generating high-quality ethically sourced datasets is crucial for enabling the use of next-generation AI technologies that transform how we do research,” said Lawrence A. Tabak, DDS, PhD, who is performing the duties of the Director of NIH. “The solutions to long-standing challenges in human health are at our fingertips, and now is the time to connect researchers and AI technologies to tackle our most difficult research questions and ultimately help improve human health.”

Ohno-Machado and Ideker components of the Bridge2AI program are funded by the NIH Common Fund (1U54HG012510-01 and 1OT2OD032742-01).

 

By: Nicole Mlynaryk - npmlynaryk@ucsd.edu

Original: https://today.ucsd.edu/story/uc-san-diego-joins-nih-bridge-to-artificial-intelligence-program

 

Appointments

To make an appointment, call
(858) 534-6290
All appointments are prioritized on the basis of medical need.

Clinic Hours

Monday - Friday
7:00am - 5:00pm
Saturday
7:45am - 2:00pm

Phone Hours

Monday - Friday
8:00am - 4:30pm
Saturday
8:00am - 2:00pm
Closed on major holidays

Email Us

Have Questions? Contacting us has never been easier. Leave us a question or comment today!

Emergency Care After Hours

For ophthalmic emergency care after hours and on weekends, please call the UCSD page operator at
(619) 543-6737
and ask for the ophthalmologist on call.

Parking Mobile App Info

Electric Vehicle Charging

Whats Your Symptom Disclaimer

The information contained in this online site is intended to provide accurate and helpful health information for the general public. It is made available with the understanding that the author and publisher are not engaged in rendering medical, health, psychological, or any other kind of personal professional services on this site. The information should not be considered complete and does not cover all diseases, ailments, physical conditions or their treatment. It should not be used in place of a call or visit to a medical, health or other competent professional, who should be consulted before adopting any of the suggestions in this site or drawing inferences from it.

The information about drugs contained on this site is general in nature. It does not cover all possible uses, actions, precautions, side effects, or interactions of the medicines mentioned, nor is the information intended as medical advice for individual problems or for making an evaluation as to the risks and benefits of taking a particular drug.

The operator(s) of this site, and the publisher, specifically disclaim all responsibility for any liability, loss or risk, personal or otherwise, which is incurred as a consequence, directly or indirectly, of the use and application of any of the material on this site.

Click Here To Accept

Email Us

First Name*
Last Name*
Email*
Phone
Topic

Required *

Submit